Through MR and a meta-analysis of rare variant genetic association studies, we confirmed that targeted inactivation and lowering of ANGPTL3, ANGPTL4, and APOC3 is associated with a reduced risk of CAD. Here, ANGPTL4 is linked to coronary artery disorder.